PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...

LONDON--(BUSINESS WIRE)--The global phosphodiesterase (PDE) inhibitors market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

May 25, 2006 — Three new studies presented here at the 2006 annual meeting of the American Urological Association support the use of phosphodiesterase-5 (PDE-5) inhibitors for the resolution of lower ...

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...

CORVALLIS, Ore., May 8, 2025 /PRNewswire/ -- Karma Biosciences announced today that it has applied for patent protection for two new drug formulations utilizing its proprietary excipient Zenergy™ .

Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.

DUBLIN--(BUSINESS WIRE)--The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...

SAN FRANCISCO -- Patients with idiopathic pulmonary fibrosis (IPF) had no disease progression when they took a novel agent targeting phosphodiesterase (PDE) 4B in a short-term study, researchers ...

There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...